Literature DB >> 9760035

Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.

T Engstrøm1, T Barth, P Melin, H Vilhardt.   

Abstract

Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin (carbetocin) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated. Apart from the parent compound two metabolites were identified namely desGlyNH2-carbetocin (carbetocin metabolite I) and desLeuGlyNH2-carbetocin (carbetocin metabolite II). Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as oxytocin. Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for oxytocin. However, maximal contractile effect of carbetocin was approximately 50% lower than that of oxytocin (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM). Neither carbetocin metabolite I nor carbetocin metabolite II were able to contract isolated myometrial tissue. All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81). These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists. All three analogues bound to the myometrial vasopressin V1 receptor, albeit with much lower affinities than to the oxytocin receptor. Carbetocin metabolite II showed the weakest binding affinity of 33.7 +/- 7.34 nM compared to 7.24 +/- 0.29 nM for carbetocin and 9.89 + 2.80 nM for carbetocin metabolite I. Only carbetocin bound to the renal vasopressin V2 receptor though the binding affinity was very low (61.3 +/- 14.6 nM).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760035     DOI: 10.1016/s0014-2999(98)00513-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice.

Authors:  Panos Zanos; Polymnia Georgiou; Sherie R Wright; Susanna M Hourani; Ian Kitchen; Raphaëlle Winsky-Sommerer; Alexis Bailey
Journal:  Neuropsychopharmacology       Date:  2013-10-15       Impact factor: 7.853

2.  The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.

Authors:  David Feifel; Paul D Shilling; Annabelle M Belcher
Journal:  Eur Neuropsychopharmacol       Date:  2011-10-01       Impact factor: 4.600

3.  Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test.

Authors:  Stella Chaviaras; Plato Mak; David Ralph; Lalitha Krishnan; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 4.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 5.  Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms.

Authors:  Ryan W Mull; Anthony Harrington; Lucia A Sanchez; Yftah Tal-Gan
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

6.  Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.

Authors:  I Passoni; M Leonzino; V Gigliucci; B Chini; M Busnelli
Journal:  J Neuroendocrinol       Date:  2016-04       Impact factor: 3.627

7.  Clearance of oxytocin and its potentially enzyme resistant analogues in the OXT-receptor compartment of the potassium depolarized rat myometrium.

Authors:  Vladimir Pliska; Guido Jutz
Journal:  J Pept Sci       Date:  2021-10-14       Impact factor: 2.408

Review 8.  Defining the Effect of Oxytocin Use in Farrowing Sows on Stillbirth Rate: A Systematic Review with a Meta-Analysis.

Authors:  Sarah V Hill; Maria Del Rocio Amezcua; Eduardo S Ribeiro; Terri L O'Sullivan; Robert M Friendship
Journal:  Animals (Basel)       Date:  2022-07-13       Impact factor: 3.231

9.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

10.  A biomimetic approach for enhancing the in vivo half-life of peptides.

Authors:  Sravan C Penchala; Mark R Miller; Arindom Pal; Jin Dong; Nikhil R Madadi; Jinghang Xie; Hyun Joo; Jerry Tsai; Patrick Batoon; Vyacheslav Samoshin; Andreas Franz; Trever Cox; Jesse Miles; William K Chan; Miki S Park; Mamoun M Alhamadsheh
Journal:  Nat Chem Biol       Date:  2015-09-07       Impact factor: 15.040

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.